MAPK8 and ischemic cardiomyopathy: In addition, genetic deletion or pharmacological inhibition of p38 MAPK, JNK, and ERK has been shown to promote hypertrophic or ischemic cardiomyopathy, indicating the cardioprotective effects of the MAPKs (58–61).